Amgen's drug meets main goal in late-stage study for rare disease

[cafead]

via Amgen (AMGN.O) said on Wednesday its drug helped to reduce the risk of flares in patients with an immune system-related condition, meeting the main goal of a late-stage study.
The drug, Uplizna, was being studied for the treatment of Immunoglobulin G4-related disease (IgG4-RD), which is characterized by periods of remission and unpredictable disease flares.

article source